Recent Research Analysts’ Ratings Updates for Spyre Therapeutics (SYRE)

by · The Cerbat Gem

Spyre Therapeutics (NASDAQ: SYRE) has recently received a number of price target changes and ratings updates:

  • 12/17/2025 – Spyre Therapeutics is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $64.00 price target on the stock.
  • 12/15/2025 – Spyre Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/8/2025 – Spyre Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/1/2025 – Spyre Therapeutics was upgraded by analysts at Jones Trading from a “hold” rating to a “buy” rating. They now have a $64.00 price target on the stock.
  • 11/25/2025 – Spyre Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/16/2025 – Spyre Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
  • 11/13/2025 – Spyre Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/8/2025 – Spyre Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.

Insider Transactions at Spyre Therapeutics

In other news, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $29.02, for a total value of $435,300.00. Following the completion of the sale, the chief executive officer owned 686,907 shares in the company, valued at $19,934,041.14. This represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.20% of the stock is currently owned by company insiders.

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Further Reading